Navigation Links
HemoShear to Present at Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) Conference
Date:4/16/2012

CHARLOTTESVILLE, Va., April 16, 2012 /PRNewswire/ -- HemoShear, LLC, a biotechnology research company and leading developer of human and animal cell-based surrogate systems for discovery and assessment of new drug compounds, has been invited to present at the American Heart Association's Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) conference.  The conference will be held April 18-20, 2012 at the Hilton Chicago, 720 South Michigan Avenue in Chicago, Illinois.

(Logo:  http://photos.prnewswire.com/prnh/20120416/PH86899LOGO )

The company will occupy booth No. six for recruiting purposes and present two scientific abstracts:

Atheroprone Hemodynamics and Oxidized Phospholipids Enhance Endothelial and Smooth Muscle Inflammatory Signaling

  • Presentation Date and Time: April 18th from 5:30pm to 7:30pm
  • Abstract ID Number: 580
  • Poster Presentation Number: 179
  • Presenter:  Ryan Feaver, Ph.D., HemoShear, Scientific Director

The Thrombotic Potential of the Endothelium Is Regulated by Hemodynamic Flow

  • Presentation Date and Time: April 20th from 8:00am to 10:00am
  • Abstract ID Number: 588
  • Poster Presentation Number: 521
  • Presenter:  Michael Simmers, Ph.D., HemoShear, Scientific Director

HemoShear team members attending the conference include Brett Blackman, Ph. D., co-founder, Chief Scientific Officer; Brian Wamhoff, Ph.D., co-founder, Vice President of Research and Development; Nicole Hastings, Ph.D., Vice President of Operations; Ryan Feaver, Ph.D., Scientific Director; Michael Simmers, Ph.D., Scientific Director.

About HemoShear, LLC

HemoShear creates human-relevant systems that accurately replicate the biology of organ systems and diseases throughout drug discovery and development.  Working in strategic partnerships with pharmaceutical, biotechnology and medical device companies, HemoShear generates meaningful data to increase confidence in decision-making, reduce risk of costly failures and identify efficacious therapies.  HemoShear's science leads to new medicines and improves human health.  


'/>"/>
SOURCE HemoShear, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. InterMune to Present at Canaccord Adams Conference
2. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
3. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
4. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CANACCORD ADAMS 28TH ANNUAL GLOBAL GROWTH CONFERENCE
5. Bionovo to Present at Canaccord Adams Global Growth Conference
6. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
7. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
8. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
9. Bluestar Silicones Presents Adhesive Gels for Wound Care at Medical Grade Polymers Conference
10. Duska Therapeutics to Present at Noble Financial Equity M.A.D. MAX Conference on Tuesday, August 19th at 1:30 p.m. PDT
11. Cepheid to Webcast Upcoming Financial Presentations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... 17, 2017  If only one in every ... mutation-conferring resistance to chemotherapy, thousands of cancer cells ... focused on finding these mutations in ever-smaller subpopulations ... tumor DNA in blood — to guide treatment ... Unfortunately, however, detecting these genetic anomalies may ...
(Date:2/16/2017)... MI (PRWEB) , ... February 16, 2017 , ... Avomeen ... p.m. The event will be held at Avomeen Analytical Services (4840 Venture Dr., ... a MichBio member organization. They provide an opportunity to interact with peers, make new ...
(Date:2/16/2017)... Feb. 16, 2017  ArmaGen, Inc., a privately ... to treat severe neurological disorders, today reported preliminary ... AGT-181, the company,s investigational therapy for the treatment ... mucopolysaccharidosis type I, or MPS I). The initial ... study, presented today at the 13 th ...
(Date:2/16/2017)... February 16, 2017 Patient ... of innovative telemedicine application, new and leading edge ... experiencing a boom worldwide. The healthcare sector as ... technologies, services and new therapies for companies such ... RHT), Cellectar Biosciences, Inc. (NASDAQ: CLRB ...
Breaking Biology Technology:
(Date:2/2/2017)... 2017   TapImmune, Inc. (NASDAQ: ... in the development of innovative peptide and gene-based ... and metastatic disease, announced today it has successfully ... a second clinical lot of TPIV 200, the ... The manufactured vaccine product will be used to ...
(Date:1/31/2017)... 31, 2017  Spero Therapeutics, LLC, a biopharmaceutical ... treatment of bacterial infections, today announced it has ... from Pro Bono Bio Ltd (PBB) to bolster ... resistant forms of Gram-negative bacteria.   The assets acquired ... a PBB group company. "The acquisition ...
(Date:1/25/2017)... YORK , Jan. 25, 2017 The ... Access Management (IAM) lifecycle is comprised of a ... for the purpose of maintaining digital identities and ... resources and applications. There are significant number of ... from time to time by optimizing processes and ...
Breaking Biology News(10 mins):